Furthermore, in the context of immunotherapy, it was shown that patients with a high degree of pre-existing and/or tumor infiltrating CD8+ T cells were more likely to respond well to PD-1/PD-L1 immune checkpoint inhibitors [69–71]. The gene discussed is CD8A; the disease is neoplasm.